Please use this identifier to cite or link to this item:
Title: Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
Authors: Hermans, Lucas Etienne
Svicher, Valentina
Pas, Suzan Diepstraten
Salpini, Romina
Alvarez, Marta
Ben Ari, Ziv
Boland, Greet
Bruzzone, Bianca
Coppola, Nicola
Seguin-Devaux, Carole
Dyda, Tomasz
Garcia, Federico
Kaiser, Rolf
Köse, Sukran
Krarup, Henrik
Lazarevic, Ivana
Lunar, Maja M
Maylin, Sarah
Micheli, Valeria
Mor, Orna
Paraschiv, Simona
Paraskevis, Dimitrios
Poljak, Mario
Puchhammer-Stöckl, Elisabeth
Simon, François
Stanojevic, Maja
Stene-Johansen, Kathrine
Tihic, Nijaz
Trimoulet, Pascale
Verheyen, Jens
Vince, Adriana
Weis, Nina
Yalcinkaya, Tülay
Lepej, Snjezana Zidovec
Perno, Carlo
Boucher, Charles A B
Wensing, Annemarie M J
HEPVIR Working Group of the European Society for Translational Antiviral Research
Keywords: antiviral drug resistance;genotypic resistance testing;hepatitis B virus;nucleos(t)ide analogs
metadata.dc.subject.mesh: Adult
Antiviral Agents
Cross-Sectional Studies
Drug Resistance, Viral
Hepatitis B virus
Hepatitis B, Chronic
Middle Aged
Issue Date: 1-Jul-2015
Abstract: European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P These findings support resistance testing in cases of apparent NA therapy failure. This survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-resistance. Continued use of these NAs needs to be reconsidered at a pan-European level.
metadata.dc.identifier.doi: 10.1093/infdis/jiv363
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.